Breast Cancer Foundation NZ
ZN-A-1041
Advanced Breast Cancer clinical trials for HER2+
Recruiting
Updated: December 4, 2024
A phase one clinical study to test safety and how well the oral drug ZN-A-1041 works by itself, or with another approved drug (PHESGO of Enhertu). As this is a phase one study, the sponsor will also be looking at how well ZN-A-1041 is tolerated and how it interacts within the body.
Criteria
- HER2+ unresectable locally-advanced metastatic breast cancer.
New Zealand
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Advanced Breast Cancer
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.